Tradestie Institutional Equity Comparison Engine

COCP vs DARE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DARE Overall Edge

DARE Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dare Bioscience, Inc. Common Stock (DARE) driven by superior Valuation, Growth & Margin while COCP counters with relative strength in Momentum & Technical. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus DARE at 1.3x Forward P/E and -813.4% operating margin (+499.6% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DARE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DARE
COCP N/M vs DARE 1.3x Fwd P/E
Growth & Margin Winner DARE
Op Margin -3063.6% vs -813.4% ยท YoY +26.9% vs +499.6%
Momentum & Technical Winner COCP
1Y -3.0% vs -67.0% ยท 52W Pos 19% vs 1%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.62
-5.13% 1D
Market Cap $12.7M
1M Return -13.93%
1Y Return -67.0%
Forward P/E 1.3x
Unified AI Score
41.3 / 100 SELL
Tech 39.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: COCP -2.96% DARE -67.0% Spread: +64.04 pp (COCP Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period COCP Revenue DARE Revenue COCP Op. Margin DARE Op. Margin Margin Edge
FY2014 N/A $0M N/A -29177.5% DARE
FY2016 N/A $0M N/A -82.3% DARE
FY2019 $10M N/A -737.4% N/A COCP
FY2020 $0M N/A -476.0% N/A COCP
FY2022 N/A $10M N/A -313.9% DARE
FY2023 N/A $0M N/A -1101.9% DARE
FY2024 N/A $0M N/A -239692.2% DARE
FY2025 N/A $0M N/A -1315.5% DARE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: COCP (4) vs DARE (4)
Institutional Metric COCP DARE Criterion Row Winner
Market Capitalization Scale $19.6M $12.7M Larger Scale Tie
Trailing P/E Ratio Valuation N/M 1.3x Lower Multiple DARE
Forward P/E Ratio Valuation N/M 1.3x Lower Multiple DARE
Revenue Growth (YoY) Growth +26.9% +499.6% Higher Growth DARE
Operating Margin (TTM) Profitability -3063.6% -813.4% Higher Margin DARE
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -311.7% -2543.1% Higher ROE COCP
52-Week Range Position Momentum 19% ($1โ€“$2) 1% ($1โ€“$4) Stronger Trend COCP
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 54% Vol 1.38ฮฒ ยท 60% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 41.3 / 100 (SELL) Higher Composite COCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full COCP vs DARE Buy Guide
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DARE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DARE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither COCP nor DARE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.